Policy Notices

• Publication of the Revised NIH Grants Policy Statement (Rev. December 2021) for Fiscal Year 2022
  (NOT-OD-22-050)
  National Institutes of Health
  

General Notices

• Notice of Clarification Regarding Institutional Eligibility for PAR-21-173 "Support for Research Excellence First Independent Research (SuRE-First) Award (R16 - Clinical Trial Not Allowed)"
  (NOT-GM-22-024)
  National Institute of General Medical Sciences
  

• Notice of Clarification Regarding Institutional Eligibility for PAR-21-169 "Support for Research Excellence (SuRE) Award (R16 Clinical Trial Not Allowed)"
  (NOT-GM-22-025)
  National Institute of General Medical Sciences
  

• Notice of NIMH Intent to Issue Funding Opportunity Announcements and Notice of Special Interest for COVID-19 and Mental Health Research
  (NOT-MH-22-105)
  National Institute of Mental Health
  

• Request for Information: Soliciting Input on Research Priorities for Amyotrophic Lateral Sclerosis (ALS)
  (NOT-NS-22-056)
  National Institute of Neurological Disorders and Stroke
  

Notice of Changes to Funding Opportunities

• Notice of Change to Key Dates for NIDA PAR-21-183, " Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)"
  (NOT-DA-22-001)
  National Institute on Drug Abuse
  

• Notice of Change to Award Information for RFA-DK-21-027, "National Centers for Metabolic Phenotyping in Live Models of Obesity and Diabetes (MPMOD) (U2C - Clinical Trial Not Allowed)"
  (NOT-DK-22-008)
  National Institute of Diabetes and Digestive and Kidney Diseases
  

• Notice of Change to Award Information for RFA-DK-21-035, "Coordinating Unit for the National Centers for Metabolic Phenotyping in Live Models of Obesity and Diabetes (MPMOD) (U24 - Clinical Trial Not Allowed)"
  (NOT-DK-22-009)
  National Institute of Diabetes and Digestive and Kidney Diseases
  

• Notice to Extend the Application Due Date for RFA-FD-22-004 - "Renewal - Cooperative Agreement to Support the Joint Institute for Food Safety and Applied Nutrition, JIFSAN (U01) Clinical Trial Not Allowed"
  (NOT-FD-22-003)
  Food and Drug Administration
  

• Notice to Extend the Application and Letter of Intent Due Dates for RFA-FD-22-013 - "Development of Advanced Analytical Methods for Analyzing Diastereomer Compositions in Oligonucleotides (U01) Clinical Trial Not Allowed"
  (NOT-FD-22-004)
  Food and Drug Administration
  

• Notice of Change to Award Budget for PHS 2021-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Grant Applications
  (NOT-OD-22-043)
  Office of the Director, NIH
  

Notices of Intent to Publish

• Notice of Intent to Publish Funding Opportunity Announcements for the RADx-UP Initiative (Phase III)
  (NOT-OD-22-051)
  Office of the Director, NIH
  National Institute of Mental Health
  

Notices of Special Interest

• Notice of Special Interest (NOSI): Novel Approaches to Diagnosing and Studying Clinical Alzheimer's Disease and Related Dementias
  (NOT-AG-21-036)
  National Institute on Aging
  

• Notice of Special Interest (NOSI): In vivo Synaptic Function in Alzheimer's Disease and Related Dementias
  (NOT-AG-21-038)
  National Institute on Aging
  

• Notice of Special Interest (NOSI): Selective Cell and Network Vulnerability in Aging and Alzheimers Disease
  (NOT-AG-21-040)
  National Institute on Aging
  

• Notice of Special Interest (NOSI): Capturing Complexity in the Molecular and Cellular Mechanisms Involved in the Etiology of Alzheimer's Disease
  (NOT-AG-21-041)
  National Institute on Aging
  

• Notice of Special Interest (NOSI): Deciphering the Glycosylation Code of Alzheimer's Disease
  (NOT-AG-21-042)
  National Institute on Aging
  

• Notice of Special Interest (NOSI): Sensory and Motor System Changes as Predictors of Preclinical Alzheimers Disease.
  (NOT-AG-21-044)
  National Institute on Aging
  

• Notice of Special Interest (NOSI): Opportunities for Research in Epidemiology of Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD) and Cognitive Resilience
  (NOT-AG-21-045)
  National Institute on Aging
  

• Notice of Special Interest (NOSI): Dementia Care Research: Programs and services for persons with dementia
  (NOT-AG-21-046)
  National Institute on Aging
  

• Notice of Special Interest (NOSI): Behavioral and Social Science Priority Areas in Dementia Care Partner/Caregiver Research
  (NOT-AG-21-047)
  National Institute on Aging
  

• Notice of Special Interest (NOSI): Digital Technology for Early Detection and Monitoring of Alzheimers Disease and Related Dementias
  (NOT-AG-21-048)
  National Institute on Aging
  

• Notice of Special Interest (NOSI): Dementia Care Workforce for Those Living with Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD)
  (NOT-AG-21-049)
  National Institute on Aging
  

• Notice of Special Interest (NOSI): Sex and Gender Differences in Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD)
  (NOT-AG-21-050)
  National Institute on Aging
  Office of Research on Women's Health
  

• Notice of Special Interest (NOSI): Human Cell Biology of Alzheimer's Disease Genetic Variants
  (NOT-AG-21-052)
  National Institute on Aging
  

• Notice of Special Interest (NOSI): Role of Age-Associated Metabolic Changes in Alzheimer's Disease
  (NOT-AG-21-053)
  National Institute on Aging
  

• Notice of Special Interest (NOSI): Disparities Affecting Healthcare Utilization and Health Outcomes Among Childhood Cancer Survivors
  (NOT-CA-22-029)
  National Cancer Institute
  

• Notice of Special Interest (NOSI): Administrative Supplements to Support Undergraduate Summer Research Experiences
  (NOT-GM-22-009)
  National Institute of General Medical Sciences
  

• Notice of Special Interest: Development and Implementation of Clinical Informatics Tools to Enhance Patients Use of Genomic Information
  (NOT-HG-22-011)
  National Human Genome Research Institute
  

• Notice of Special Interest (NOSI): BRAIN Initiative: Translation of Groundbreaking Technologies from Early-stage Development through Early Clinical Study via Blueprint MedTech
  (NOT-NS-22-052)
  National Institute of Neurological Disorders and Stroke
  National Center for Complementary and Integrative Health
  National Eye Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Mental Health
  Office of Behavioral and Social Sciences Research
  

Funding Opportunities

• Limited Competition: Development and Renovation of Housing, Breeding, and Research Spaces for Existing NIH-supported NHP Colonies (C06 Clinical Trial Not Allowed)
  (PAR-21-363)
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
  Application Receipt Date(s): March 15, 2022
  
  

• Emergency Awards: HEAL Initiative: Translational Science Career Enhancement Awards for Early and Mid-career Investigators (K18 Clinical Trials Not Allowed)
  (PAR-22-057)
  National Center for Advancing Translational Sciences
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  National Institute of Neurological Disorders and Stroke
  Office of Research on Women's Health
  Application Receipt Date(s): January 20, 2022
  
  

• High-End Instrumentation (HEI) Grant Program (S10 Clinical Trial Not Allowed)
  (PAR-22-079)
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
  National Institute of General Medical Sciences
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Shared Instrumentation Grant (SIG) Program (S10 Clinical Trial Not Allowed)
  (PAR-22-080)
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
  National Institute of General Medical Sciences
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Limited Competition: Basic Instrumentation Grant (BIG) Program (S10 Clinical Trial Not Allowed)
  (PAR-22-081)
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
  National Institute of General Medical Sciences
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Biomedical Research Facilities (C06 Clinical Trial Not Allowed)
  (PAR-22-088)
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
  Application Receipt Date(s): March 25, 2022
  
  

• NIA Renewal and Competing Revision Cooperative Agreements in Aging Research (U01 Clinical Trial Optional)
  (PAR-22-362)
  National Institute on Aging
  Application Receipt Date(s): Not Applicable
  
  

• Coordinating Center for the Claude D. Pepper Older Americans Independence Centers (OAICs) (U24 Clinical Trial Optional)
  (RFA-AG-23-006)
  National Institute on Aging
  Application Receipt Date(s): May 16, 2022
  
  

• Pharmacokinetic and Pharmacodynamic (PK/PD) Studies of mTOR Inhibitors on Aging-Related Indications (U01 Clinical Trial Required)
  (RFA-AG-23-008)
  National Institute on Aging
  Application Receipt Date(s): June 15, 2022
  
  

• Host Immunity and Novel Immunization Strategies for Clostridioides difficile Infection (CDI) (U19 Clinical Trial Not Allowed)
  (RFA-AI-22-001)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): May 20, 2022
  
  

• Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)
  (RFA-CA-22-005)
  National Cancer Institute
  Application Receipt Date(s): September 22, 2022
  
  

• Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional)
  (RFA-CA-22-006)
  National Cancer Institute
  Application Receipt Date(s): September 22, 2022
  
  

• Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U54 Clinical Trials Optional)
  (RFA-CA-22-007)
  National Cancer Institute
  Application Receipt Date(s): September 22, 2022
  
  

• Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P01 Clinical Trial Optional)
  (RFA-CA-22-008)
  National Cancer Institute
  Application Receipt Date(s): September 22, 2022
  
  

• Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)
  (RFA-CA-22-009)
  National Cancer Institute
  Application Receipt Date(s): September 22, 2022
  
  

• Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U2C Clinical Trial Optional)
  (RFA-CA-22-010)
  National Cancer Institute
  Application Receipt Date(s): September 22, 2022
  
  

• U.S. and Low- and Middle-Income Country (LMIC) HIV-Associated Malignancy Research Centers (U54 Clinical Trial Optional)
  (RFA-CA-22-011)
  National Cancer Institute
  John E. Fogarty International Center
  Application Receipt Date(s): March 30, 2022
  
  

• HEAL Initiative: HEAL Data2Action Modeling and Economic Resource Center (U24 Clinical Trial Optional)
  (RFA-DA-22-049)
  National Institute on Drug Abuse
  National Center for Complementary and Integrative Health
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Application Receipt Date(s): March 10, 2022
  
  

• HEAL Initiative: HEAL Data2Action Research Adoption Support Center (U2C Clinical Trial Optional)
  (RFA-DA-22-050)
  National Institute on Drug Abuse
  National Center for Complementary and Integrative Health
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Application Receipt Date(s): March 25, 2022
  
  

• HEAL Initiative: HEAL Data2Action Innovation Projects (R61/R33 Clinical Trial Optional)
  (RFA-DA-22-051)
  National Institute on Drug Abuse
  National Center for Complementary and Integrative Health
  Application Receipt Date(s): March 10, 2022
  
  

• HEAL Initiative: HEAL Data2Action (HD2A) Data Infrastructure Support Center (U24 Clinical Trial Optional)
  (RFA-DA-22-052)
  National Institute on Drug Abuse
  National Center for Complementary and Integrative Health
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Application Receipt Date(s): March 10, 2022
  
  

• Elucidating the heterogeneity of impaired awareness of hypoglycemia in Type 1 Diabetes (T1D) Clinical Centers (U01 Clinical Trial Required)
  (RFA-DK-21-020)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): March 31, 2022
  
  

• Elucidating the heterogeneity of impaired awareness of hypoglycemia in Type 1 Diabetes (T1D) - Biostatistics Research Center (U01 Clinical Trial Not Allowed)
  (RFA-DK-21-036)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): March 31, 2022
  
  

• Maintaining and Enriching Environmental Epidemiology Cohorts to Support Scientific and Workforce Diversity (U24 Clinical Trial Not Allowed)
  (RFA-ES-22-001)
  National Institute of Environmental Health Sciences
  Application Receipt Date(s): November 03, 2022
  
  

• Physician Scientist Transition to Independence in Blood Science Research (R00 - Clinical Trial Optional)
  (RFA-HL-23-003)
  National Heart, Lung, and Blood Institute
  Application Receipt Date(s): March 28, 2024
  
  

• Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Clinical Trial Optional)
  (RFA-MD-22-003)
  National Institute on Minority Health and Health Disparities
  National Center for Advancing Translational Sciences
  Application Receipt Date(s): April 04, 2022
  
  

• Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional)
  (RFA-MD-22-004)
  National Institute on Minority Health and Health Disparities
  National Center for Advancing Translational Sciences
  National Heart, Lung, and Blood Institute
  National Institute on Aging
  National Institute of Biomedical Imaging and Bioengineering
  National Institute on Drug Abuse
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of Mental Health
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): April 04, 2022
  
  

• Advancing communication strategies to support future HIV vaccine use (R01 Clinical Trial Optional)
  (RFA-MH-22-170)
  National Institute of Mental Health
  National Institute on Drug Abuse
  Office of Behavioral and Social Sciences Research
  Application Receipt Date(s): May 10, 2022
  
  

• Advancing communication strategies to support future HIV vaccine use (R21 Clinical Trial Optional)
  (RFA-MH-22-171)
  National Institute of Mental Health
  National Institute on Drug Abuse
  Office of Behavioral and Social Sciences Research
  Application Receipt Date(s): May 10, 2022
  
  

• Stroke Preclinical Assessment Network (SPAN) to Support Translational Studies for Acute Cerebroprotection - Testing Laboratories (U01 Clinical Trial Not Allowed)
  (RFA-NS-22-003)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): March 14, 2022
  
  

• Limited Competition: Stroke Preclinical Assessment Network (SPAN) to Support Translational Studies for Acute Cerebroprotection - Coordinating Center (U24 Clinical Trial Not Allowed)
  (RFA-NS-22-004)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): March 14, 2022
  
  

• Stroke Preclinical Assessment Network (SPAN) to Support Translational Studies For Acute Cerebroprotection- Interventions (U01 Clinical Trial Not Allowed)
  (RFA-NS-22-032)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): March 14, 2022
  
  

• Stroke Preclinical Assessment Network (SPAN) to Support Translational Studies for Acute Cerebroprotection- Interventions from Small Businesses (U44 Clinical Trial Not Allowed)
  (RFA-NS-22-033)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): March 14, 2022
  
  

• HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed)
  (RFA-NS-22-034)
  National Institute of Neurological Disorders and Stroke
  National Center for Advancing Translational Sciences
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute of Dental and Craniofacial Research
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): Multiple dates, see announcement.